Reports Q2 revenue $1.627M vs $1.43M last year. Michael Poirier, Qualigen’s Chairman and CEO commented, “2023 has been a transformative year for Qualigen Therapeutics. Despite continued industry headwinds, we significantly advanced our oncology-focused pipeline within budget and timelines. To build on our momentum, the company recently achieved two major milestones: We received US FDA Investigational New Drug clearance to initiate a Phase 1 clinical trial for QN-302, a small molecule G-Quadruplex-selective transcription inhibitor for treatment of advanced or metastatic solid tumors, and we divested our FastPack diagnostics business.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QLGN:
- Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
- Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
- Qualigen announces U.S. FDA IND clearance to initiate Phase 1 trial of QN-302
- Qualigen Therapeutics Divests FastPack® Diagnostics Business
- Qualigen Therapeutics divests FastPack Diagnostics business
